Linda Avey is the co-founder and CEO of Precisely (precise.ly), designing a new approach to delivering lower cost healthcare services through patient-centered automation.
In 2006 Linda envisioned and co-founded 23andMe, the world’s largest consumer-driven genetics research database (NASDAQ: ME). Her experience in the nascent ‘whole genome’ field of study, and the need for more human participants, led to her concept of the 23andMe research model, which links genetic data to health information from the company’s millions of users. This is now fueling the discovery of potential drug targets and supporting pharmaceutical partnerships valued in the hundreds of millions USD.
Linda is on the advisory board of Alphabet's life science subsidiary Verily, is a member of the Board of Fellows of Stanford Medical School, and is an advisor to George Church’s new venture Colossal Bio. She was the founding independent board director at Rock Health, the first venture fund dedicated to digital health, where she advised startups ideating new ways of delivering healthcare.